Viking Therapeutics VKTX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $118.12M+211% | $165.81M+522% | $100.38M+99.4% | $33.88M-22.9% | $37.94M-80.6% | ||
| $484.85M-40.4% | $539.93M-38.4% | $614.19M-30.2% | $773.84M-13.9% | $813.92M+6.1% | ||
| $1.22M+41.5% | $1.81M+60.1% | $2.24M+29.4% | $2.82M+1,940% | $865K+34.5% | ||
| $608.21M-29.8% | $715.6M-21.1% | $738.7M-21.1% | $827.02M-12.6% | $866.02M-10.4% | ||
| $0-100% | $85K-91.5% | $666K-40.2% | $780K-20.2% | $892K-15.2% | ||
| $33K-28.3% | $46K0.0% | $46K0.0% | $46K+39.4% | $46K+39.4% | ||
| $608.24M-29.8% | $715.73M-21.2% | $739.42M-21.2% | $827.85M-12.6% | $866.99M-10.4% | ||
| $67.18M+772% | $53.25M+443% | $4.41M+1,637% | $5.49M-50.5% | $7.7M+47.4% | ||
| $39.14M+244% | $23.28M+36.0% | $21.22M-15.0% | $26.02M+90.3% | $11.37M-58.2% | ||
| $0-100% | $137K-72.0% | $437K-9.0% | $468K+40.1% | $498K+51.4% | ||
| $106.33M+443% | $76.67M+180% | $26.07M+1.5% | $31.98M+27.4% | $19.57M-40.3% | ||
| $0-100% | $137K-87.8% | $755K-38.9% | $878K-20.2% | $1M-15.3% | ||
| $106.33M+430% | $76.67M+173% | $26.39M-0.2% | $32.39M+25.3% | $20.08M-40.3% | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | ||
| $1.51B+9.3% | $1.49B+8.6% | $1.4B+3.0% | $1.39B+3.3% | $1.38B+3.0% | ||
| -$1.01B-88.5% | -$847.55M-73.7% | -$689.88M-52.5% | -$599.1M-40.1% | -$533.54M-31.6% | ||
| -$856K-296% | $378K+148% | $374K-77.1% | -$166K+92.7% | -$216K+86.5% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $501.92M-40.7% | $639.06M-27.4% | $713.03M-21.8% | $795.46M-13.6% | $846.92M-9.3% | ||
| $608.24M-29.8% | $715.73M-21.2% | $739.42M-21.2% | $827.85M-12.6% | $866.99M-10.4% | ||
| $484.85M-40.4% | $539.93M-38.4% | $614.19M-30.2% | $773.84M-13.9% | $813.92M+6.1% | ||
| $4.02M-69.8% | $8.05M+132% | $21.89M+389% | $16.48M+396% | $13.3M+390% | ||
| $33K-28.3% | $46K0.0% | $46K0.0% | $46K+39.4% | $46K+39.4% | ||
| $0-100% | $85K-91.5% | $666K-40.2% | $780K-20.2% | $892K-15.2% | ||
| $0-100% | $85K-91.5% | $666K-40.2% | $780K-20.2% | $892K-15.2% | ||
| $0-100% | $85K-91.5% | $666K-40.2% | $780K-20.2% | $892K-15.2% | ||
| —— | $137K-87.8% | $755K-38.9% | $878K-20.2% | $1M-15.3% | ||
| -$856K-296% | $378K+148% | $374K-77.1% | -$166K+92.7% | -$216K+86.5% | ||
| $1.51B+9.3% | $1.49B+8.6% | $1.4B+3.0% | $1.39B+3.3% | $1.38B+3.0% | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | ||
| $39.14M+244% | $23.28M+36.0% | $21.22M-15.0% | $26.02M+90.3% | $11.37M-58.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Viking Therapeutics cover its short-term obligations?
- Its current ratio is 5.72 — current assets exceed current liabilities.
- Where does Viking Therapeutics's balance sheet data come from?
- Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.